Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Taniborbactam

From Wikipedia, the free encyclopedia

Pharmaceutical compound
Taniborbactam
Clinical data
Other namesVNRX-5133, VNRX5133
Legal status
Legal status
  • Investigational
Identifiers
  • (3R)-3-[[2-[4-(2-Aminoethylamino)cyclohexyl]acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H28BN3O5
Molar mass389.26 g·mol−1
3D model (JSmol)
  • O=C(O)C1=CC=CC2=C1OB(O)[C@@H](NC(C[C@@H]3CC[C@@H](NCCN)CC3)=O)C2
  • InChI=InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
  • Key:PFZUWUXKQPRWAL-PXCJXSSVSA-N

Taniborbactam (development codeVNRX-5133) is a pharmaceutical drug that acts as aβ-lactamase inhibitor.[1] It inhibits the function of bacterialβ-lactamases which impart resistance toβ-lactam antibiotics. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of theNew Delhi metallo-beta-lactamase 1 group which are the most frequently identified sources of acquired antibiotic resistance worldwide.[2]

Taniborbactam, in combination withcefepime, is in clinical trials for the treatment of bacterial infections, includingurinary tract infection andpyelonephritis.[3][4]

References

[edit]
  1. ^Liu B, Trout RE, Chu GH, McGarry D, Jackson RW, Hamrick JC, et al. (March 2020)."Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections".Journal of Medicinal Chemistry.63 (6):2789–2801.doi:10.1021/acs.jmedchem.9b01518.PMC 7104248.PMID 31765155.
  2. ^Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L (April 2023). "NDM-9 resistance to taniborbactam".The Lancet. Infectious Diseases.23 (4):401–402.doi:10.1016/S1473-3099(23)00069-5.PMID 36796395.
  3. ^Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. (February 2024). "Cefepime-Taniborbactam in Complicated Urinary Tract Infection".The New England Journal of Medicine.390 (7):611–622.doi:10.1056/NEJMoa2304748.PMID 38354140.
  4. ^"Cefepime/taniborbactam - VenatoRx Pharmaceuticals".AdisInsight. Springer Nature Switzerland AG.
Stub icon

Thisantiinfectivedrug article is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Taniborbactam&oldid=1338296554"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp